Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647 1654 1672
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18609758 | TIE2-BINDING AGENTS AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18612561 | Modulation of Heparin-Binding Epidermal Growth Factor Activity for Tympanic Membrane Healing | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18054284 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES | Final Rejection | Eli Lilly and Company |
| 17916664 | AFFINITY MATURED ANTI-LAP ANTIBODIES AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18580810 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18182323 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18059180 | SYSTEM AND METHODS FOR INCREASING SYNTHESIZED PROTEIN STABILITY | Non-Final OA | Board of Regents, The University of Texas System |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | Final Rejection | GENZYME CORPORATION |
| 17408937 | TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | Final Rejection | Sanofi |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy